The relationship between homoarginine and liver biomarkers: a combination of epidemiological and clinical studies
Abstract Homoarginine (hArg) is a non-essential cationic amino acid which inhibits hepatic alkaline phosphatases to exert inhibitory effects on bile secretion by targeting intrahepatic biliary epithelium. We analyzed (1) the relationship between hArg and liver biomarkers in two large population-base...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-03-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-023-32363-4 |
| _version_ | 1827974565239717888 |
|---|---|
| author | Ali Aghdassi Edzard Schwedhelm Dorothee Atzler Matthias Nauck Jens-Peter Kühn Marie-Luise Kromrey Henry Völzke Stephan B. Felix Marcus Dörr Till Ittermann Martin Bahls |
| author_facet | Ali Aghdassi Edzard Schwedhelm Dorothee Atzler Matthias Nauck Jens-Peter Kühn Marie-Luise Kromrey Henry Völzke Stephan B. Felix Marcus Dörr Till Ittermann Martin Bahls |
| author_sort | Ali Aghdassi |
| collection | DOAJ |
| description | Abstract Homoarginine (hArg) is a non-essential cationic amino acid which inhibits hepatic alkaline phosphatases to exert inhibitory effects on bile secretion by targeting intrahepatic biliary epithelium. We analyzed (1) the relationship between hArg and liver biomarkers in two large population-based studies and (2) the impact of hArg supplementation on liver biomarkers. We assessed the relationship between alanine transaminase (ALT), aspartate aminotransferase (AST), γ-glutamyltransferase (GGT), alkaline phosphatases (AP), albumin, total bilirubin, cholinesterase, Quick’s value, liver fat, and Model for End-stage Liver Disease (MELD) and hArg in appropriately adjusted linear regression models. We analyzed the effect of L-hArg supplemention (125 mg L-hArg daily for 4 weeks) on these liver biomarkers. We included 7638 individuals (men: 3705; premenopausal women: 1866, postmenopausal women: 2067). We found positive associations for hArg and ALT (β 0.38 µkatal/L 95% confidence interval (CI): 0.29; 0.48), AST (β 0.29 µkatal/L 95% CI 0.17; 0.41), GGT (β 0.033 µkatal/L 95% CI 0.014; 0.053), Fib-4 score (β 0.08 95% CI 0.03; 0.13), liver fat content (β 0.016% 95% CI 0.006; 0.026), albumin (β 0.030 g/L 95% CI 0.019; 0.040), and cholinesterase (β 0.003 µkatal/L 95% CI 0.002; 0.004) in males. In premenopausal women hArg was positively related with liver fat content (β 0.047% 95%CI 0.013; 0.080) and inversely with albumin (β − 0.057 g/L 95% CI − 0.073; − 0.041). In postmenopausal women hARG was positively associated with AST (β 0.26 µkatal/L 95% CI 0.11; 0.42). hArg supplementation did not affect liver biomarkers. We summarize that hArg may be a marker of liver dysfunction and should be explored further. |
| first_indexed | 2024-04-09T19:56:28Z |
| format | Article |
| id | doaj.art-6b6d7a76147d463293a7657a9f664666 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-09T19:56:28Z |
| publishDate | 2023-03-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-6b6d7a76147d463293a7657a9f6646662023-04-03T05:27:09ZengNature PortfolioScientific Reports2045-23222023-03-011311810.1038/s41598-023-32363-4The relationship between homoarginine and liver biomarkers: a combination of epidemiological and clinical studiesAli Aghdassi0Edzard Schwedhelm1Dorothee Atzler2Matthias Nauck3Jens-Peter Kühn4Marie-Luise Kromrey5Henry Völzke6Stephan B. Felix7Marcus Dörr8Till Ittermann9Martin Bahls10Department of Medicine A – Gastroenterology, Nephrology, Endocrinology and Rheumatology, University Medicine GreifswaldInstitute of Clinical Pharmacology and Toxicology, University Medical Center Hamburg-EppendorfInstitute of Clinical Pharmacology and Toxicology, University Medical Center Hamburg-EppendorfWalther Straub Institute of Pharmacology and Toxicology, Ludwig-Maximilians-UniversitätInstitute and Policlinic for Diagnostic and Interventional Radiology, University Hospital, Carl Gustav Carus UniversityInstitute for Radiology and Neuroradiology, University Medicine GreifswaldDZHK (German Center for Cardiovascular Research), Partner Site GreifswaldDZHK (German Center for Cardiovascular Research), Partner Site GreifswaldDZHK (German Center for Cardiovascular Research), Partner Site GreifswaldDZHK (German Center for Cardiovascular Research), Partner Site GreifswaldDZHK (German Center for Cardiovascular Research), Partner Site GreifswaldAbstract Homoarginine (hArg) is a non-essential cationic amino acid which inhibits hepatic alkaline phosphatases to exert inhibitory effects on bile secretion by targeting intrahepatic biliary epithelium. We analyzed (1) the relationship between hArg and liver biomarkers in two large population-based studies and (2) the impact of hArg supplementation on liver biomarkers. We assessed the relationship between alanine transaminase (ALT), aspartate aminotransferase (AST), γ-glutamyltransferase (GGT), alkaline phosphatases (AP), albumin, total bilirubin, cholinesterase, Quick’s value, liver fat, and Model for End-stage Liver Disease (MELD) and hArg in appropriately adjusted linear regression models. We analyzed the effect of L-hArg supplemention (125 mg L-hArg daily for 4 weeks) on these liver biomarkers. We included 7638 individuals (men: 3705; premenopausal women: 1866, postmenopausal women: 2067). We found positive associations for hArg and ALT (β 0.38 µkatal/L 95% confidence interval (CI): 0.29; 0.48), AST (β 0.29 µkatal/L 95% CI 0.17; 0.41), GGT (β 0.033 µkatal/L 95% CI 0.014; 0.053), Fib-4 score (β 0.08 95% CI 0.03; 0.13), liver fat content (β 0.016% 95% CI 0.006; 0.026), albumin (β 0.030 g/L 95% CI 0.019; 0.040), and cholinesterase (β 0.003 µkatal/L 95% CI 0.002; 0.004) in males. In premenopausal women hArg was positively related with liver fat content (β 0.047% 95%CI 0.013; 0.080) and inversely with albumin (β − 0.057 g/L 95% CI − 0.073; − 0.041). In postmenopausal women hARG was positively associated with AST (β 0.26 µkatal/L 95% CI 0.11; 0.42). hArg supplementation did not affect liver biomarkers. We summarize that hArg may be a marker of liver dysfunction and should be explored further.https://doi.org/10.1038/s41598-023-32363-4 |
| spellingShingle | Ali Aghdassi Edzard Schwedhelm Dorothee Atzler Matthias Nauck Jens-Peter Kühn Marie-Luise Kromrey Henry Völzke Stephan B. Felix Marcus Dörr Till Ittermann Martin Bahls The relationship between homoarginine and liver biomarkers: a combination of epidemiological and clinical studies Scientific Reports |
| title | The relationship between homoarginine and liver biomarkers: a combination of epidemiological and clinical studies |
| title_full | The relationship between homoarginine and liver biomarkers: a combination of epidemiological and clinical studies |
| title_fullStr | The relationship between homoarginine and liver biomarkers: a combination of epidemiological and clinical studies |
| title_full_unstemmed | The relationship between homoarginine and liver biomarkers: a combination of epidemiological and clinical studies |
| title_short | The relationship between homoarginine and liver biomarkers: a combination of epidemiological and clinical studies |
| title_sort | relationship between homoarginine and liver biomarkers a combination of epidemiological and clinical studies |
| url | https://doi.org/10.1038/s41598-023-32363-4 |
| work_keys_str_mv | AT aliaghdassi therelationshipbetweenhomoarginineandliverbiomarkersacombinationofepidemiologicalandclinicalstudies AT edzardschwedhelm therelationshipbetweenhomoarginineandliverbiomarkersacombinationofepidemiologicalandclinicalstudies AT dorotheeatzler therelationshipbetweenhomoarginineandliverbiomarkersacombinationofepidemiologicalandclinicalstudies AT matthiasnauck therelationshipbetweenhomoarginineandliverbiomarkersacombinationofepidemiologicalandclinicalstudies AT jenspeterkuhn therelationshipbetweenhomoarginineandliverbiomarkersacombinationofepidemiologicalandclinicalstudies AT marieluisekromrey therelationshipbetweenhomoarginineandliverbiomarkersacombinationofepidemiologicalandclinicalstudies AT henryvolzke therelationshipbetweenhomoarginineandliverbiomarkersacombinationofepidemiologicalandclinicalstudies AT stephanbfelix therelationshipbetweenhomoarginineandliverbiomarkersacombinationofepidemiologicalandclinicalstudies AT marcusdorr therelationshipbetweenhomoarginineandliverbiomarkersacombinationofepidemiologicalandclinicalstudies AT tillittermann therelationshipbetweenhomoarginineandliverbiomarkersacombinationofepidemiologicalandclinicalstudies AT martinbahls therelationshipbetweenhomoarginineandliverbiomarkersacombinationofepidemiologicalandclinicalstudies AT aliaghdassi relationshipbetweenhomoarginineandliverbiomarkersacombinationofepidemiologicalandclinicalstudies AT edzardschwedhelm relationshipbetweenhomoarginineandliverbiomarkersacombinationofepidemiologicalandclinicalstudies AT dorotheeatzler relationshipbetweenhomoarginineandliverbiomarkersacombinationofepidemiologicalandclinicalstudies AT matthiasnauck relationshipbetweenhomoarginineandliverbiomarkersacombinationofepidemiologicalandclinicalstudies AT jenspeterkuhn relationshipbetweenhomoarginineandliverbiomarkersacombinationofepidemiologicalandclinicalstudies AT marieluisekromrey relationshipbetweenhomoarginineandliverbiomarkersacombinationofepidemiologicalandclinicalstudies AT henryvolzke relationshipbetweenhomoarginineandliverbiomarkersacombinationofepidemiologicalandclinicalstudies AT stephanbfelix relationshipbetweenhomoarginineandliverbiomarkersacombinationofepidemiologicalandclinicalstudies AT marcusdorr relationshipbetweenhomoarginineandliverbiomarkersacombinationofepidemiologicalandclinicalstudies AT tillittermann relationshipbetweenhomoarginineandliverbiomarkersacombinationofepidemiologicalandclinicalstudies AT martinbahls relationshipbetweenhomoarginineandliverbiomarkersacombinationofepidemiologicalandclinicalstudies |